Levine Media Group

05/09/2025

Robin Williams, assistant professor at the University of Minnesota Masonic Children's Hospital, describes the case of Avion, a 15-year-old who became critically ill when he was admitted into a pediatric intensive care unit. She discusses the medical puzzle she couldn’t crack on her own, and what it took to diagnose him with the ultra-rare disease TAFRO, a form of idiopathic multicentric Castleman’s disease. Global Genes

Robin Williams, assistant professor of pediatric hematology/oncology at the University of Minnesota Masonic Children's Hospital, describes the case of Avion, a 15-year-old who became critically ill when he was admitted into a pediatric intensive care unit, the medical puzzle she couldn’t crack on ...

03/09/2025

Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients.

https://thebioreport.podbean.com/e/using-targeted-radiotherapies-to-treat-challenging-cns-cancers/

27/08/2025

Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics.

https://thebioreport.podbean.com/e/hitting-previously-undruggable-targets-with-oral-therapies/

22/08/2025

Tris Dyson, managing director of Challenge Works, discusses his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease. Global Genes

Tris Dyson, managing director of Challenge Works, about his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease.

20/08/2025

Stacey Adam, vice president of scientific partnerships for the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the range of technologies they are exploring, and how they have the potential to accelerate drug development and transform biomedical research.

https://thebioreport.podbean.com/e/building-better-models-of-human-diseases-to-speed-drug-development/

15/08/2025

Daniel Fischer, CEO of Tevard Biosciences, discusses his own journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that promise to treat a broad range of diseases with a single genetic medicine. Global Genes

Daniel Fischer, CEO of Tevard Biosciences, discusses his own journey as the parent of a child with the rare epilepsy Dravet syndrome, how it led to his co-founding Tevard and its pursuit of tRNA therapies, and why this type of genetic medicine holds promise for so many people with rare diseases.

14/08/2025

The State of AI in Clinical Development.

Dimitris K. Agrafiotis, Director of Digital Analytics and AI at Arsenal Capital Partners, joins host Nagaraja Srivatsan to discuss why AI will have a bigger near-term impact on improving operational overhead than on driving novel science.

Tune in to explore how AI is streamlining processes, reducing costs, and shaping the future of clinical development.

https://www.agilisium.com/podcast/why-ais-most-promising-near-term-value-is-in-clinical-operations

hashtag hashtag hashtag hashtag hashtag hashtag

Discover Dr. Dimitris Agrafiotis, a global leader in AI, data science, and healthcare innovation. Renowned for building enterprise-wide solutions, fostering collaboration, and driving digital transformation in life sciences.

13/08/2025

Lorin Johnson, chief scientific officer of Glycyx, discusses the effect of opioids on the immune system, the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors, and why its drug in development may promote gut health in these patients more broadly.

https://thebioreport.podbean.com/e/preventing-opioids-from-countering-the-benefits-of-cancer-immunotherapies/

08/08/2025

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the biological difference between hunger and appetite, and why his company’s experimental therapy to treat the condition may have broader applications in other forms of obesity. Global Genes

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the company’s experimental therapy to treat the condition, and why it may have broader applications in other forms of obesity.

06/08/2025

Abbas Kazimi, CEO of computational chemistry innovator Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals.

https://thebioreport.podbean.com/e/better-living-through-computational-chemistry/

01/08/2025

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts.

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts. If you enjoy our content, be sure to like, comment, and subscribe on your preferred platform.

31/07/2025

David B. Goldstein, founder and CEO of Actio Biosciences, Inc., discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing may represent a challenge. Global Genes

David Goldstein, founder and CEO of Actio Biosciences, discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing represents a challenge for such a business model.